FDA Clears New Neurosurgical Port for Deep Brain Access

Megan Brooks


September 10, 2020

The US Food and Drug Administration (FDA) has granted marketing clearance to the MindsEye Expandable Port (Minnetronix Medical) for deep brain access during neurosurgical procedures, the company announced.

The MindsEye port is the first minimally invasive, expandable, and retractable port designed for use in the treatment of stroke, cancer, and other conditions, the company said.

It's a single-use disposable device with a proprietary flexible sheath and removable obturator that is compatible with modern surgical navigation systems.

The dynamic retraction feature is a "big step forward over current fixed, wide diameter ports," Matt Adams, vice president and general manager at Minnetronix Medical, told Medscape Medical News.

"Dynamic retraction allows the surgeon to control the size of the working channel from as little as 6 mm to a­­s large as 20 mm, all on-demand. It does less damage and provides a flexible approach that allows surgeons to stay in control of the channel and ease on surrounding tissue," Adams said.­­

"This is next-generation deep brain access technology," Mario Zuccarello, MD, professor of neurosurgery, University of Cincinnati Medical Center, Ohio, added in a company news release.

"Minimizing invasiveness as much as possible is important to respect the eloquence of brain tissue. The MindsEye Expandable Port allows surgeons to work without unnecessary distractions, which ultimately improves quality of life for the patient," he added.

The company said it is actively exploring distribution options in the United States.

For more Medscape Neurology news, join us on Facebook and Twitter.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.